Page 57 - Query Get News Today

Patients with keratoconus and relatively regular astigmatism can benefit from toric IOLs, provided that keratoconus-specific formulae are used for lens power calculation, according to a speaker.“Our results showed that the Barrett True-K formula provided the most accurate IOL power,” Ehud Assia, MD, said at the European Society of Cataract and Refractive Surgeons meeting.

Prescription digital therapeutic company Limbix announced the launch of a digital tool for teens and young adults with depression symptoms. The therapeutic, SparkRx, incorporates cognitive behavioral therapy and is meant to serve as an adjunct treatment for individuals aged 13 to 22 years.

Plasma osteopontin levels are significantly higher in children hospitalized with moderate to severe COVID-19 and MIS-C than in those with mild or asymptomatic cases, suggesting a potential biomarker for disease severity, researchers said. “There are currently no reliable biomarkers for COVID-19 or multisystem inflammatory syndrome, or MIS-C,” Andrew Reisner, MD, of Children’s

The effectiveness of the Pfizer-BioNTech vaccine against any SARS-CoV-2 infection was about 20% among patients in Qatar 5 to 7 months after administration of the second dose, a study in The New England Journal of Medicine showed. However, vaccine effectiveness against COVID-19-related hospitalization or death “persisted with hardly any waning for 6 months after the second dose,”

Patient-reported psoriasis signs and symptoms improvement was significantly better in those treated with deucravacitinib over placebo and apremilast, according to two clinical trials presented at the EADV Congress virtual meeting.“Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor that binds to the regulatory domain with high specificity,” April Armstrong,

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer. The agency placed the hold on the trials after the manufacturer reported one patient with pretreated stage IV follicular lymphoma who received its ALLO-501A CAR T cells in the ALPHA2 study

Remo Panaccione, MD, of the University of Calgary, reported Rinvoq safely and effectively maintained moderate-to-severe ulcerative colitis. “Upadacitinib, which is on the market as Rinvoq [AbbVie] for rheumatoid arthritis, is expected to be approved in 2022 for the treatment of moderate to severe ulcerative colitis,” Panaccione said. “Seeing these impressive

Measurement-based care decreased depression severity, promoted remission and improved medication adherence among patients with depressive disorders treated with pharmacotherapy, according to a study.“Measurement-based care (MBC) is an evidence-based practice that provides a systematic framework for routine outcome monitoring and has demonstrated benefit in treating a range of psychiatric

An anterior segment OCT study showed that the corneas of children who frequently rub their eyes have abnormal epithelial thickness distribution, with thinning in the inferotemporal area on the dominant-hand side.“This thinning could represent one of the earliest stages of keratoconus,” Tomás Loureiro, MD, said at the European Society of Cataract and Refractive Surgeons meeting.

Upadacitinib significantly reduced signs and symptoms of both ankylosing spondylitis and nonradiographic axial spondyloarthritis, as well as improved physical function and disease activity, according to a pair of phase 3 studies from AbbVie. Both studies from the SELECT-AXIS 2 clinical trial. In the first, upadacitinib (Rinvoq, AbbVie) met the primary endpoint of Assessment in Spondyloarthritis